Download full-text PDF |
Source |
---|
Urol Pract
December 2024
Urology Division, Hartford HealthCare Medical Group, Hartford, Connecticut.
Urol Pract
December 2024
Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Anal Chem
January 2025
School of Environmental & Chemical Engineering, Jiangsu University of Science and Technology, Changhui Rd. 666, Zhenjiang, Jiangsu 212003, China.
Early diagnosis of tumors allows effective treatment of primary cancers through localized therapeutic interventions. However, developing diagnostic tools for sensitive, simple, and early tumor (especially less than 2 mm in diameter) detection remains a challenge. Herein, we presented a biomarker-activatable nanoprobe that enabled a near-infrared (NIR) photothermally amplified signal for fluorescence imaging and urinalysis of tumor.
View Article and Find Full Text PDFStem Cell Res Ther
January 2025
Department of Medicine, Veterans Affairs Medical Center, Washington, DC, USA.
Introduction: Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.
Hypothesis: We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.
Tomography
January 2025
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Objectives: Accurate kidney and tumor segmentation of computed tomography (CT) scans is vital for diagnosis and treatment, but manual methods are time-consuming and inconsistent, highlighting the value of AI automation. This study develops a fully automated AI model using vision transformers (ViTs) and convolutional neural networks (CNNs) to detect and segment kidneys and kidney tumors in Contrast-Enhanced (CECT) scans, with a focus on improving sensitivity for small, indistinct tumors.
Methods: The segmentation framework employs a ViT-based model for the kidney organ, followed by a 3D UNet model with enhanced connections and attention mechanisms for tumor detection and segmentation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!